Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Aviso Financial Inc. Grows Stock Holdings in Sanofi $SNY
03:32am, Tuesday, 25'th Nov 2025
Aviso Financial Inc. boosted its holdings in shares of Sanofi (NASDAQ: SNY) by 4.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). Th
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Bristol Myers, Sanofi sued by Texas over Plavix
04:06pm, Thursday, 20'th Nov 2025
Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
12:20pm, Tuesday, 18'th Nov 2025
Burlington, Massachusetts--(Newsfile Corp. - November 18, 2025) - Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of aut
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
12:00pm, Tuesday, 18'th Nov 2025
BURLINGTON, Mass.--(BUSINESS WIRE)-- #ADCs--Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammato
Bank of New York Mellon Corp Sells 1,452,581 Shares of Sanofi $SNY
04:30am, Sunday, 16'th Nov 2025
Bank of New York Mellon Corp lowered its stake in Sanofi (NASDAQ: SNY) by 74.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund
Sanofi's type 1 diabetes drug recommended for EU approval
08:21am, Friday, 14'th Nov 2025
The European Medicines Agency's committee has recommended approval of French drugmaker Sanofi's first-of-its-kind drug that delays onset of the insulin-dependent stage 3 of type 1 diabetes, it said on
Press Release: Sanofi's Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
06:30am, Friday, 14'th Nov 2025
Sanofi's Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild's ability to delay the onset of stag
Traders Buy Large Volume of Put Options on Sanofi (NASDAQ:SNY)
01:10am, Wednesday, 12'th Nov 2025
Sanofi (NASDAQ: SNY - Get Free Report) saw unusually large options trading activity on Tuesday. Investors bought 30,724 put options on the stock. This represents an increase of approximately 1,171% co
The Zacks Analyst Blog Accenture, Sanofi and Dell
02:21am, Tuesday, 11'th Nov 2025
Chicago, IL – November 11, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting sto
ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
08:47pm, Monday, 27'th Oct 2025
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care Expanded 10-plus-year collaboration will levera
Sanofi: Is Dupixent Too Successful?
02:32pm, Friday, 24'th Oct 2025
Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help addre
